{"entity":{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","aka":["TROPION-PanTumor03"],"tldr":"A phase 2 trial of Datopotamab deruxtecan, Capecitabine, Fluorouracil in endometrial cancer and prostate cancer, run by AstraZeneca, now recruiting.","summary":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03). ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 454 participants. Primary completion is estimated at 2027-10-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin. Registered primary measures: Objective response rate (ORR); The number of subjects with adverse events/serious adverse events; PSA50 response (Substudy 3 only).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05489211","url":"https://clinicaltrials.gov/study/NCT05489211"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial","prostate","ovarian","colorectal"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["datopotamab-deruxtecan","capecitabine","fluorouracil","carboplatin","bevacizumab","rilvegostomig"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 454 participants. Primary completion is estimated at 2027-10-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05489211","phase":"2","setting":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","sponsor":"AstraZeneca","participation":[{"nct":"NCT05489211","source":"https://clinicaltrials.gov/study/NCT05489211","fetchedAt":"2026-10-07T16:53:43.406Z","studySha256":"96d28cdac1441676bdd18d3d79f65ba1cfd1971033da0de225200b2a2eda53cb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":454,"enrolmentType":"ESTIMATED","siteCount":96,"recruitingSiteCount":56,"countries":["Canada","China","France","Germany","Italy","Japan","Poland","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2022-09-06","startedType":"actual","enrolled":454,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05489211/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}